Article    Table of Contents                    Full Text of this article Free    PDF of this article (PDFs free after 6 months)    Summary for Patients    Summary for Patients (PDF)    Figures/Tables List    Related articles in Annals  Services    Send comment/rapid response letter    Published comments/rapid response letters    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Al-Khatib, S. M.    Califf, R. M.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Clinical and Economic Implications of the Multicenter Automatic Defibrillator Implantation Trial-II

Sana M. Al-Khatib, MD, MHS; Kevin J. Anstrom, PhD; Eric L. Eisenstein, DBA; Eric D. Peterson, MD, MPH; James G. Jollis, MD; Daniel B. Mark, MD, MPH; Yun Li, MS; Christopher M. O'Connor, MD; Linda K. Shaw, MS; and Robert M. Califf, MD

19 April 2005 | Volume 142 Issue 8 | Pages 593-600

Background: The Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II demonstrated that implantable cardioverter defibrillators (ICDs) save lives when used in patients with a history of myocardial infarction (MI) and an ejection fraction of 0.3 or less.

Objective: To investigate the cost-effectiveness of implanting ICDs in patients who met MADIT-II eligibility criteria and were enrolled in the Duke Cardiovascular Database between 1 January 1986 and 31 December 2001.

Design: Cost-effectiveness analysis.

Data Sources: Published literature, databases owned by Duke University Medical Center, and Medicare data.

Target Population: Adults with a history of MI and an ejection fraction of 0.3 or less.

Time Horizon: Lifetime.

Perspective: Societal.

Interventions: ICD therapy versus conventional medical therapy.

Outcomes Measures: Cost per life-year gained and incremental cost-effectiveness.

Results: Compared with conventional medical therapy, ICDs are projected to result in an increase of 1.80 discounted years in life expectancy and an incremental cost-effectiveness ratio of $50 500 per life-year gained. Cost-effectiveness varied dramatically with changes in time horizon: The cost-effectiveness ratio increased to $67 800 per life-year gained, $79 900 per life-year gained, $100 000 per life-year gained, $167 900 per life-year gained, and $367 200 per life-year gained for 15-year, 12-year, 9-year, 6-year, and 3-year time horizons, respectively. Changing the frequency of follow-up visits, complication rates, and battery replacements had less of an effect on the cost-effectiveness ratios than reducing the cost of ICD placement and leads.

Limitations: The study was limited by the completeness of the data, referral bias, difference in medical therapy between the Duke cohort and the MADIT-II cohort, and not addressing potential upgrades to biventricular devices.

Conclusions: The economic expense of defibrillator implantation in all patients who meet MADIT-II eligibility criteria is substantial. However, in the range of survival benefit observed in MADIT-II, ICD therapy for these patients is economically attractive by conventional standards.

Editors' Notes Context The Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II has shown that implantable cardioverter defibrillators (ICDs), compared with conventional therapy, appreciably improve survival in patients who have had a myocardial infarction and have an ejection fraction of 0.3 or less. However, the cost of following these recommendations has not been adequately assessed. Contribution Implantable cardioverter defibrillators are projected to improve survival by 1.80 discounted years, with an incremental cost-effectiveness ratio of $50 500 per life-year gained. Sensitivity analysis shows that the cost of replacing ICD batteries and leads exerts greater effect on cost-effectiveness ratios than other factors. Implications The large number of patients eligible for ICDs under MADIT-II criteria may strain societal ability to perform and pay for these procedures. –The Editors

 

Author and Article Information

From the Duke Clinical Research Institute, Durham, North Carolina.

The results of this study were presented at the American College of Cardiology 52nd Annual Scientific Session, Chicago, Illinois, 30 March–2 April 2003.

Acknowledgments: The authors thank Kerry Lee, PhD, for critical review of the manuscript and Maqui Ortiz for editorial assistance and manuscript preparation.

Grant Support: In part by Guidant Corporation.

Potential Financial Conflicts of Interest: Consultancies: S.M. Al-Khatib (Guidant Corp.), D.B. Mark (Medtronic Inc.), C.M. O'Connor (Guidant Corp., Medtronic Inc.), R.M. Califf (Guidant Corp., Medtronic Inc.); Honoraria: S.M. Al-Khatib (Medtronic Inc., Guidant Corp.), D.B. Mark (Medtronic Inc.), C.M. O'Connor (Guidant Corp., Medtronic Inc.), R.M. Califf (Guidant Corp., Medtronic Inc.); Stock ownership or options (other than mutual funds): R.M. Califf (Guidant Corp., Medtronic Inc.); Grants received: S.M. Al-Khatib (Guidant Corp., Medtronic Inc.), D.B. Mark (Medtronic Inc.), R.M. Califf (Guidant Corp., Medtronic Inc.); Grants pending: D.B. Mark (Medtronic Inc.), R.M. Califf (Guidant Corp., Medtronic Inc.); Royalties: R.M. Califf (Guidant Corp., Medtronic Inc.).

Requests for Single Reprints: Sana M. Al-Khatib, MD, Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715.

Current Author Addresses: Drs. Al-Khatib, Anstrom, Peterson, Jollis, Mark, O'Connor, and Califf; Mr. Li; Mr. Eisenstein; and Ms. Shaw: Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27715.

Author Contributions: Conception and design: S.M. Al-Khatib, K.J. Anstrom, E.L. Eisenstein, J.G. Jollis, C.M. O'Connor, R.M. Califf.

Analysis and interpretation of the data: S.M. Al-Khatib, K.J. Anstrom, E.L. Eisenstein, E.D. Peterson, J.G. Jollis, D.B. Mark, Y. Li, C.M. O'Connor, L.K. Shaw.

Drafting of the article: S.M. Al-Khatib, K.J. Anstrom, E.L. Eisenstein, D.B. Mark.

Critical revision of the article for important intellectual content: K.J. Anstrom, E.L. Eisenstein, E.D. Peterson, J.G. Jollis, D.B. Mark, Y. Li, C.M. O'Connor, L.K. Shaw, R.M. Califf.

Final approval of the article: S.M. Al-Khatib, K.J. Anstrom, E.D. Peterson, J.G. Jollis, D.B. Mark, Y. Li, C.M. O'Connor, L.K. Shaw, R.M. Califf.

Provision of study materials or patients: E.D. Peterson.

Statistical expertise: K.J. Anstrom, E.D. Peterson, Y. Li, L.K. Shaw.

Obtaining of funding: S.M. Al-Khatib, R.M. Califf.

Administrative, technical, or logistic support: R.M. Califf.

Collection and assembly of data: S.M. Al-Khatib, K.J. Anstrom, Y. Li, L.K. Shaw.

Related articles in Annals:

Academia and Clinic
The Ethics of Deactivating Implanted Cardioverter Defibrillators
Jeffrey T. Berger

Annals 2005 142: 631-634. [ABSTRACT][Full Text]  

Editorials
Preventing Sudden Cardiac Death: Can We Afford the Benefit?
Stephen G. Pauker, N. A. Mark Estes, AND Deeb N. Salem

Annals 2005 142: 664-666. [Full Text]  

Summaries for Patients
What Are the Clinical and Economic Implications of Following MADIT-II Criteria for Surgically Implanting Automatic Cardiac Defibrillators?

Annals 2005 142: I-39. [Full Text]  

Letters
Implications of the Multicenter Automatic Defibrillator Implantation Trial-II
William S. Weintraub

Annals 2006 144: 65. [Full Text]  

Letters
Implications of the Multicenter Automatic Defibrillator Implantation Trial-II
Fahim H. Jafary

Annals 2006 144: 65. [Full Text]  

Letters
Implications of the Multicenter Automatic Defibrillator Implantation Trial-II
Sana M. Al-Khatib, Daniel B. Mark, AND Robert M. Califf

Annals 2006 144: 65-66. [Full Text]  

This article has been cited by other articles:

				A. E. Epstein Benefits of the Implantable Cardioverter-Defibrillator J. Am. Coll. Cardiol., September 30, 2008; 52(14): 1122 - 1127. [Abstract] [Full Text] [PDF]

				M. Biffi, M. Ziacchi, M. Bertini, D. Sangiorgi, D. Corsini, C. Martignani, I. Diemberger, and G. Boriani Longevity of implantable cardioverter-defibrillators: implications for clinical practice and health care systems Europace, September 3, 2008; (2008) eun240v1. [Abstract] [Full Text] [PDF]

				J.-P. Couderc, W. Zareba, S. McNitt, P. Maison-Blanche, and A. J. Moss Repolarization variability in the risk stratification of MADIT II patients Europace, September 1, 2007; 9(9): 717 - 723. [Abstract] [Full Text] [PDF]

				J. A. Ezekowitz, B. H. Rowe, D. M. Dryden, N. Hooton, B. Vandermeer, C. Spooner, and F. A. McAlister Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction Ann Intern Med, August 21, 2007; 147(4): 251 - 262. [Abstract] [Full Text] [PDF]

				T. Chow, D. J. Kereiakes, C. Bartone, T. Booth, E. J. Schloss, T. Waller, E. Chung, S. Menon, B. K. Nallamothu, and P. S. Chan Microvolt T-Wave Alternans Identifies Patients With Ischemic Cardiomyopathy Who Benefit From Implantable Cardioverter-Defibrillator Therapy J. Am. Coll. Cardiol., January 2, 2007; 49(1): 50 - 58. [Abstract] [Full Text] [PDF]

				D. R. Davis, A. S.L. Tang, R. Lemery, M. S. Green, M. H. Gollob, and D. H. Birnie Influence of gender on ICD implantation for primary and secondary prevention of sudden cardiac death Europace, December 1, 2006; 8(12): 1054 - 1056. [Abstract] [Full Text] [PDF]

				P. S. Chan, T. Chow, D. Kereiakes, E. J. Schloss, T. Waller, K. Eagle, R. A. Hayward, and S. Vijan Effectiveness of implantable cardioverter-defibrillators in patients with ischemic heart disease and left ventricular dysfunction. Arch Intern Med, November 13, 2006; 166(20): 2228 - 2233. [Abstract] [Full Text] [PDF]

				D. B. Mark, C. L. Nelson, K. J. Anstrom, S. M. Al-Khatib, A. A. Tsiatis, P. A. Cowper, N. E. Clapp-Channing, L. Davidson-Ray, J. E. Poole, G. Johnson, et al. Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure: Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Circulation, July 11, 2006; 114(2): 135 - 142. [Abstract] [Full Text] [PDF]

				P. S. Chan, K. Stein, T. Chow, M. Fendrick, J. T. Bigger, and S. Vijan Cost-Effectiveness of a Microvolt T-Wave Alternans Screening Strategy for Implantable Cardioverter-Defibrillator Placement in the MADIT-II-Eligible Population J. Am. Coll. Cardiol., July 4, 2006; 48(1): 112 - 121. [Abstract] [Full Text] [PDF]

				M. R. Reynolds, D. J. Cohen, A. D. Kugelmass, P. P. Brown, E. R. Becker, S. D. Culler, and A. W. Simon The Frequency and Incremental Cost of Major Complications Among Medicare Beneficiaries Receiving Implantable Cardioverter-Defibrillators J. Am. Coll. Cardiol., June 20, 2006; 47(12): 2493 - 2497. [Abstract] [Full Text] [PDF]

				J. Zwanziger, W. J. Hall, A. W. Dick, H. Zhao, A. I. Mushlin, R. M. Hahn, H. Wang, M. L. Andrews, C. Mooney, H. Wang, et al. The Cost Effectiveness of Implantable Cardioverter-Defibrillators: Results From the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II J. Am. Coll. Cardiol., June 6, 2006; 47(11): 2310 - 2318. [Abstract] [Full Text] [PDF]

				J M Morgan, J C Cowan, A J Camm, and J M McComb Sudden cardiac death: opportunities for prevention Heart, June 1, 2006; 92(6): 721 - 723. [Abstract] [Full Text] [PDF]

				T. Chow, D. J. Kereiakes, C. Bartone, T. Booth, E. J. Schloss, T. Waller, E. S. Chung, S. Menon, B. K. Nallamothu, and P. S. Chan Prognostic Utility of Microvolt T-Wave Alternans in Risk Stratification of Patients With Ischemic Cardiomyopathy J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1820 - 1827. [Abstract] [Full Text] [PDF]

				W. S. Weintraub Implications of the Multicenter Automatic Defibrillator Implantation Trial-II Ann Intern Med, January 3, 2006; 144(1): 65 - 65. [Full Text] [PDF]

				F. H. Jafary Implications of the Multicenter Automatic Defibrillator Implantation Trial-II Ann Intern Med, January 3, 2006; 144(1): 65 - 65. [Full Text] [PDF]

				Cost-Effectiveness of ICDs for MADIT-II-Eligible Patients Journal Watch Cardiology, June 10, 2005; 2005(610): 3 - 3. [Full Text]

				A. Tonks What's new in the other general journals BMJ, May 7, 2005; 330(7499): 1045 - 1045. [Full Text] [PDF]

				S. G. Pauker, N. A. M. Estes, and D. N. Salem Preventing Sudden Cardiac Death: Can We Afford the Benefit? Ann Intern Med, April 19, 2005; 142(8): 664 - 666. [Full Text] [PDF]

Rapid Responses: